These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Vascular responses to vasopressin antagonists in man and rat. Burrell LM; Phillips PA; Rolls KA; Buxton BF; Johnston CI; Liu JJ Clin Sci (Lond); 1994 Oct; 87(4):389-95. PubMed ID: 7834989 [TBL] [Abstract][Full Text] [Related]
6. Human internal mammary artery responses to non-peptide vasopressin antagonists. Liu JJ; Phillips PA; Burrell LM; Buxton BB; Johnston CI Clin Exp Pharmacol Physiol; 1994 Feb; 21(2):121-4. PubMed ID: 8039263 [TBL] [Abstract][Full Text] [Related]
7. Orally active, nonpeptide vasopressin V1 antagonists. A novel series of 1-(1-substituted 4-piperidyl)-3,4-dihdyro-2(1H)-quinolinone. Ogawa H; Yamamura Y; Miyamoto H; Kondo K; Yamashita H; Nakaya K; Chihara T; Mori T; Tominaga M; Yabuuchi Y J Med Chem; 1993 Jul; 36(14):2011-7. PubMed ID: 8393113 [TBL] [Abstract][Full Text] [Related]
8. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Yamamura Y; Ogawa H; Chihara T; Kondo K; Onogawa T; Nakamura S; Mori T; Tominaga M; Yabuuchi Y Science; 1991 Apr; 252(5005):572-4. PubMed ID: 1850553 [TBL] [Abstract][Full Text] [Related]
9. Organic osmolytes in rat renal inner medulla are modulated by vasopressin V1 and/or V2 antagonists. Nakanishi T; Yamauchi A; Nakahama H; Yamamura Y; Yamada Y; Orita Y; Fujiwara Y; Uyeda N; Takamitsu Y; Sugita M Am J Physiol; 1994 Jul; 267(1 Pt 2):F146-52. PubMed ID: 8048555 [TBL] [Abstract][Full Text] [Related]
10. Blocking effects of V1 (OPC-21268) and V2 (OPC-31260) antagonists on the negative inotropic response to vasopressin in isolated dog heart preparations. Furukawa Y; Takayama S; Ren LM; Sawaki S; Inoue Y; Chiba S J Pharmacol Exp Ther; 1992 Nov; 263(2):627-31. PubMed ID: 1331408 [TBL] [Abstract][Full Text] [Related]
11. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Yamamura Y; Ogawa H; Yamashita H; Chihara T; Miyamoto H; Nakamura S; Onogawa T; Yamashita T; Hosokawa T; Mori T Br J Pharmacol; 1992 Apr; 105(4):787-91. PubMed ID: 1387020 [TBL] [Abstract][Full Text] [Related]
12. Distinct mechanisms of action of V1 antagonists OPC-21268 and [d(CH2)5Tyr(Me)AVP] in mesangial cells. Jamil KM; Watanabe T; Nakao A; Okuda T; Kurokawa K Biochem Biophys Res Commun; 1993 Jun; 193(2):738-43. PubMed ID: 8390252 [TBL] [Abstract][Full Text] [Related]
13. In vitro macro- and microautoradiographic localization of V1 and V2 receptors in the rat kidney using OPC-21268 and OPC-31260. Mimura Y; Ogura T; Hayakawa N; Otsuka F; Hashimoto M; Yamauchi T; Makino H; Ogawa N Nephron; 1997; 76(3):331-6. PubMed ID: 9226235 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of vasopressin action in vascular smooth muscle by the V1 antagonist OPC-21268. Li X; Kribben A; Wieder ED; Tsai P; Nemenoff RA; Schrier RW Hypertension; 1994 Feb; 23(2):217-22. PubMed ID: 8307632 [TBL] [Abstract][Full Text] [Related]
15. Effects of the non-peptide inhibitor OPC-21268 on oxytocin and vasopressin stimulation of rat and human myometrium. Atke A; Vilhardt H; Hauzerova L; Barth T; Andersen LF Eur J Pharmacol; 1995 Jul; 281(1):63-8. PubMed ID: 8566118 [TBL] [Abstract][Full Text] [Related]
16. Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat. Burrell LM; Phillips PA; Stephenson JM; Risvanis J; Rolls KA; Johnston CI Hypertension; 1994 Jun; 23(6 Pt 1):737-43. PubMed ID: 8206571 [TBL] [Abstract][Full Text] [Related]
17. Effect of a new V1 antagonist (OPC-21268) on vascular action of vasopressin in cultured rat vascular smooth muscle cells. Okada K; Ishikawa S; Saito T Biochem Biophys Res Commun; 1991 Jul; 178(2):707-12. PubMed ID: 1650196 [TBL] [Abstract][Full Text] [Related]
18. C-terminal deletions in agonistic and antagonistic analogues of vasopressin that improve their specificities for antidiuretic (V2) and vasopressor (V1) receptors. Manning M; Misicka A; Olma A; Klis WA; Bankowski K; Nawrocka E; Kruszynski M; Kolodziejczyk A; Cheng LL; Seto J J Med Chem; 1987 Dec; 30(12):2245-52. PubMed ID: 2960812 [TBL] [Abstract][Full Text] [Related]
19. Receptor subtype for vasopressin-induced release of nitric oxide from rat kidney. Hirata Y; Hayakawa H; Kakoki M; Tojo A; Suzuki E; Nagata D; Kimura K; Goto A; Kikuchi K; Nagano T; Hirobe M; Omata M Hypertension; 1997 Jan; 29(1 Pt 1):58-64. PubMed ID: 9039081 [TBL] [Abstract][Full Text] [Related]
20. [Arg8]vasopressin-induced responses of the human isolated coronary artery: effects of non-peptide receptor antagonists. Bax WA; Van der Graaf PH; Stam WB; Bos E; Nisato D; Saxena PR Eur J Pharmacol; 1995 Oct; 285(2):199-202. PubMed ID: 8566139 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]